NOT-NS-19-020: Notice of Clarification to Language for Project Characteristics in PAR-18-549, Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)

Notice of Clarification to Language for Project Characteristics in PAR-18-549, Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)

Notice Number: NOT-NS-19-020

Key Dates
Release Date: November 8, 2018

Related Announcements
PAR-18-549

PAR-18-550

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this Notice is to clarify language for bullet four of the Project Characteristics section in Part. 2. Section I, Funding Opportunity Description for PAR-18-549.

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Project Characteristics

Current Language for bullet four:

Applications to this FOA should use technologies already in use or soon to be approved for use in clinical laboratories since this is not a technology development FOA.

Revised Language for bullet four:

The biomarker detection method must be developed and ready for validation studies.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Mary Ann Pelleymounter, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: [email protected]